TY  - JOUR
T1  - Formulation and Evaluation of Favipiravir Proliposomal Powder for Pulmonary Delivery by Nebulization
A1  - Naseeb Basha Shaik
A1  - Lakshmi PK
A1  - Basava Rao VV
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2022
VL  - 11
IS  - 2
DO  - 10.51847/4McfhPccXs
SP  - 36
EP  - 44
N2  - The favipiravir proliposomal is a powder formulation for pulmonary delivery by nebulization, prepared and characterized by film deposition on carrier method. The formulations have good flow properties and upon hydration, liposome vesicles were seen within 2-3 minutes. According to the results of SEM studies the surface morphology was coarse and non-porous. The DSC and XRD studies confirm that the favipiravir drug is crystalline, whereas the FPL6 is amorphous. In-vitro nebulization studies performed using a twin stage impinger (TSI) revealed that the nebulization time ranges from 12.95 to 14.3 minutes. The aerosol mass output and rate ranges from 44.31 to 54.28 %, and 0.17 to 0.22 mg/min. respectively. The respirable fraction ranges from 8.14 to 12.31%. The FPL6 formulation has a higher respirable fraction of 12.31%, which is available for therapeutic action in the lungs and stable. The results showed that the favipiravir proliposomal formulation was suitable for pulmonary drug delivery via nebulization. 
UR  - https://ijpras.com/article/formulation-and-evaluation-of-favipiravir-proliposomal-powder-for-pulmonary-delivery-by-nebulization-vmbmx7fjghbcq9n
ER  -